Colesevelam
- TRADE NAMES: Cholestagel (Genzyme); Welchol (Sankyo)
- INDICATIONS: Hypercholesterolemia, hyperlipidemia, Type II diabetes mellitus
- CLASS: Bile acid sequestrant
- HALF-LIFE: N/A
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Cyclosporine, Deferasirox, Estradiol, Glyburide, Levothyroxine, Olmesartan, Phenytoin, Warfarin
PREGNANCY CATEGORY: B
Contra-indicated in patients with a history of bowel obstruction, with serum triglyceride concentrations >500 mg/dL or with a history of hypertriglyceridemia-induced pancreatitis.
Please login to see the rest of this drug profile
SKIN.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
RESPIRATORY.
OTHER.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of colesevelam in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 07/31/2023
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric
